Alzheimer'
Conditions
Interventions
1) PET ligand: [18F]AM-PBB3 administration dose: 10mCi number of dose: single dose 2) PET ligand: [11C]PBB3 administration dose: (body weight(kg)/5)mCi number of dose: single dose 3) PET liga
Sponsors
National Institute of Radiological Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy subjects: 1. Healthy subjects who have the ability to consent to participate in this study 2. 20 years of age or older at the time of obtaining consent Dementia subjects: 1. 20 years of age or older at the time of obtaining consent. 2. Subjects who can be accompanied by a legal guardian on the day of study participation at the NIRS. 3. Subjects meeting the inclusion criteria in the J-ADNI core study except for age. However, the range of CDR (Clinical dementia rating) in patients with AD will be 0.5-2, and the range of MMSE (Mini Mental State Examination) will be 26 points or less
Exclusion criteria
Exclusion criteria: 1. Subjects who show obviously abnormal blood data at 1st day of the study 2. Subjects with organic brain complications/disorders (including a history of traumatic brain injury, symptomatic cerebral infarction, Parkinson's disease and similar conditions) 3. Patients with substance-related disorders (including drug abuse) 4. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study 5. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.) 6. Subjects with tattoos 7. Subjects with claustrophobia 8. Pregnant, possibly pregnant or lactating women 9. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 12 months prior to the start of this study 10. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic and quantitative analysis of [18F]AM-PBB3 Effective dose of [18F]AM-PBB3 | — |
Countries
Japan
Contacts
Public ContactKazuko Suzuki
National Institute of Radiological Sciences Molecular Imaging Center
Outcome results
None listed